Skip to main content

CUTR

Stock
Health Care
Medical Devices

Performance overview

CUTR Price
Price Chart

Forward-looking statistics

Beta
1.95
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.

Company info

SectorHealth Care
IndustryMedical Devices
Employees658
Market cap$38.5M

Fundamentals

Enterprise value$376.4M
Revenue$155.2M
Revenue per employee—
Profit margin-92.59%
Debt to equity-1.71

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.18
Dividend per share—
Revenue per share$7.74
Avg trading volume (30 day)$699
Avg trading volume (10 day)$69
Put-call ratio—

Macro factor sensitivity

Growth+6.6
Credit+7.8
Liquidity-4.5
Inflation+1.9
Commodities+2.2
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio-0.03
Price to sales0.01
P/E Ratio-0.03
Enterprise Value to Revenue2.42
Price to book-0.00

Upcoming events

Next earnings dayMay 10, 2024
Next dividend day—
Ex. dividend day—

News

Cutera (CUTR) Reports Q3 Loss, Misses Revenue Estimates

Cutera (CUTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.61 per share a year ago.

Zacks Investment Research (November 7, 2024)
Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (October 6, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free